Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives


Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) is a combination hormone medicine which is indicated for use by females of reproductive potential for prevention of pregnancy. It is also used for the treatment of moderate acne vulgaris in women more than 14 years of age who, have no known contraindications to oral contraceptive therapy, desire contraception, and have achieved menarche.
© All Contraceptives
Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets)

Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives The active pharmaceutical ingredients contained in Ovral-L tablets are Ethinyl Estradiol and Levonorgestrel. Each Ovral-L Contraceptive tablet contains 0.03 mg (30 mcg) Ethinyl Estradiol and 0.15 mg (150 mcg) Levonorgestrel. Active Ingredients


Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives Chemical Structure - Levonorgestrel


Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives Chemical Structure – Ethinyl Estradiol


Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives Ovral-L Tablets Ovral-L Tablets are manufactured by Wyeth Limited, India, a division of Pfizer. Ovral-L is available as tablets containing 0.03 mg Ethinyl Estradiol and 0.15 mg Levonorgestrel . (Website: https://www.pfizerindia.com/ )
URL: https://www.allcontraceptives.com/ovral-l-tablets.html

Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives Uses of Ovral-L Tablets

URL: https://www.allcontraceptives.com/ovral-l-tablets.html
Levonorgestrel and Ethinyl Estradiol combination (Ovral-L tablets) is used to prevent pregnancy. It works by stopping a woman's egg from fully developing each month. The egg can no longer accept a sperm and fertilization (pregnancy) is prevented. Besides preventing pregnancy, birth control pills may make your periods more regular, decrease blood loss and painful periods, decrease your risk of ovarian cysts, and also treat acne. This medicine will not prevent HIV infection or other sexually transmitted diseases. It will not help as emergency contraception, such as after unprotected sexual contact.
https://www.allcontraceptives.com/ovral-l-tablets.html
Levonorgestrel
URL:
Ovral-L
Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives Uses of Ovral-L Tablets

hormonal
The decision to prescribe Ovral-L (Generic Ethinyl Estradiol and Tablets) should take into consideration the individual woman's current risk factors, particularly those for thromboembolism (VTE), and how the risk of VTE with tablets compares with other combined contraceptives (CHCs).
venous
Tablets should be taken exactly as directed and at intervals not exceeding 24 hours. The next pack should start 7 days after the last active tablet was taken.
The dosage of is one Ovral-L tablet daily for 21 consecutive days.
First treatment cycle: 1 tablet daily for 21 days, starting on the first day of the menstrual cycle. Contraceptive protection begins immediately.

The dosage of Ovral-L tablets (Generic Ethinyl Estradiol and Levonorgestrel Tablets) is given below:
Tablets must be taken orally in the order directed on the blister package at about the same time every day, with some liquid if necessary.
© All Contraceptives Recommended Dosage
URL: https://www.allcontraceptives.com/ovral-l-tablets.html
Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets)
Changing from 21-day combined oral contraceptives: The first tablet of Ovral-L should be taken on the first day immediately after the end of the previous oral contraceptive course. Additional contraceptive precautions are not required.

URL: https://www.allcontraceptives.com/ovral-l-tablets.html
Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets)
The dosage of Ovral-L tablets (Generic Ethinyl Estradiol and Levonorgestrel Tablets) is given below:
© Contraceptives Recommended Dosage
All
Subsequent cycles: Tablet-taking from the next pack of Ovral-L is continued after a 7-day tablet-free interval, beginning on the same day of the week as the first pack. A withdrawal bleed usually occurs during the tablet-free interval.
Changing from a combined Every Day pill (28 -day tablets): Ovral-L should be started after taking the last active tablet from the Every Day Pill pack. The first Ovral-L tablet is taken the next day. Additional contraceptive precautions are not then required.

© All Contraceptives Recommended Dosage
Changing from a progestogen-only pill (POP): The first tablet of OvralL should be taken on the first day of bleeding, even if a POP has already been taken on that day. Additional contraceptive precautions are not then required. The remaining progestogen-only pills should be discarded.
Ovral-L Tablets)
URL: https://www.allcontraceptives.com/ovral-l-tablets.html
(Generic Ethinyl Estradiol and Levonorgestrel
The dosage of Ovral-L tablets (Generic Ethinyl Estradiol and Levonorgestrel Tablets) is given below:
Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives Contraindications Ovral-L tablets are contraindicated in persons with a hypersensitivity (allergy) to Ethinyl Estradiol, Levonorgestrel or any of the other ingredients of this medicine. Combination oral contraceptives should not be used in women with any of the following conditions: Thrombophlebitis or thromboembolic disorders A history of deep-vein thrombophlebitis or thromboembolic disorders Cerebrovascular or coronary artery disease (current or past history) Valvular heart disease with thrombogenic complications Thrombogenic rhythm disorders URL: https://www.allcontraceptives.com/ovral-l-tablets.html

Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives Contraindications Combination oral contraceptives should not be used in women with any of the following conditions: Hereditary or acquired thrombophilias Major surgery with prolonged immobilization Diabetes with vascular involvement Headaches with focal neurological symptoms Uncontrolled hypertension Known or suspected carcinoma of the breast or personal history of breast Carcinomacancer of the endometrium or other known or suspected estrogendependent neoplasia. URL: https://www.allcontraceptives.com/ovral-l-tablets.html

Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives Contraindications Combination oral contraceptives should not be used in women with any of the following conditions: Undiagnosed abnormal genital bleeding Cholestatic jaundice of pregnancy or jaundice with prior pill use Hepatic adenomas or carcinomas, or active liver disease Known or suspected pregnancy URL: https://www.allcontraceptives.com/ovral-l-tablets.html

Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives Storage Instructions Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) have to be stored at controlled room temperature i.e. from 20°C to 25°C (68°F to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F). Keep this as well as all other medicines away from children and pets. URL: https://www.allcontraceptives.com/ovral-l-tablets.html

Cigarette smoking increases the risk of serious cardiovascular side effects from oral-contraceptive use. This risk increases with age and with the extent of smoking and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets)

© All Contraceptives Warnings
Vascular Events: Stop Combined oral contraceptives (COCs) such as Ovral-L (Ethinyl Estradiol and Levonorgestrel Tablets) if an arterial or deep venous thrombotic event occurs. Although use of COCs increases the risk of venous thromboembolism, pregnancy increases the risk of venous thromboembolism as much or more than the use of COCs. Carcinoma of the Breast and Cervix: Women who currently have or have had breast cancer should not use COCs because breast cancer may be hormonally sensitive.
Liver Disease: Stop using COCs if jaundice develops. Steroid hormones may be poorly metabolized in patients with impaired liver function. Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment: During clinical trials with the Hepatitis C combination drug regimen that contains Obmitasvir / Paritaprevir / Ritonavir, with or without Dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using Ethinyl Estradiol-containing medications, such as COCs. Discontinue Ovral-L (Ethinyl Estradiol and Levonorgestrel Tablets) prior to starting therapy with the combination medicine regimen.
(Generic Ethinyl Estradiol and Levonorgestrel

© All Contraceptives Warnings
High Blood Pressure:For women with well-controlled hypertension, monitor blood pressure and stop COCs if blood pressure rises significantly. Women with uncontrolled hypertension or hypertension with vascular disease should not use COCs.
Ovral-L Tablets)
Headache: If a woman taking Combined oral contraceptives develops new headaches that are recurrent, persistent, or severe, evaluate the cause as well as significant change in headaches and discontinue COCs if indicated.

© All Contraceptives Warnings
Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets)
Carbohydrate and Lipid Metabolic Effects: Carefully monitor prediabetic and diabetic women who are taking COCs. COCs may decrease glucose tolerance in a dose-related fashion.
Bleeding Irregularities: Unscheduled (breakthrough) bleeding and spotting sometimes occur in patients on Combined oral contraceptives, especially during the first 3 months of use. If bleeding persists, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different Combined oral contraceptive medicine.
Gallbladder Disease: Studies suggest a small increased relative risk of developing gallbladder disease among COC users.
lipids, glucose tolerance, and binding
Monitoring:proteins.
some laboratory tests, such as coagulation
Uterine
© results of factors,
All Contraceptives Warnings Interference with Laboratory Tests: The use of Combined oral contraceptives could change the
A woman who is taking Combined oral contraceptives should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare.

bleeding: Evaluate irregular bleeding or amenorrhea.
Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets)
Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives Ovral-L Tablets Side Effects Common Side effects of Ethinyl Estradiol and Levonorgestrel tablets (Ovral-L ) in 5% or more of women during clinical trials were: headaches (33%); irregular and/or heavy uterine bleeding (13%), dysmenorrhea (11%), nausea and/or vomiting (11%), back pain (8%). Other side effects include: vulvovaginal candidiasis, breakthrough bleeding, decreased glucose tolerance, increased blood pressure, migraine, spotty menstruation, vaginitis, dizziness, abdominal cramps, abdominal distention, acne vulgaris, breast tension and breast changes. URL: https://www.allcontraceptives.com/ovral-l-tablets.html

© All Contraceptives
There have been no reports of serious adverse effects from overdose, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea. There is no specific antidote for Ovral-L overdosage and further treatment of overdose, if necessary, is directed to the symptoms.

Ovral-L Tablets) Overdose
URL: https://www.allcontraceptives.com/ovral-l-tablets.html
(Generic Ethinyl Estradiol and Levonorgestrel
Ethinyl tablets ) Category X. There is little birth defects inadvertently contraceptives during early pregnancy.
Estradiol and Levonorgestrel
following exposure to low dose Combined oral contraceptives

or non-genital
Epidemiologic studies and meta-analyses have not found risk of genital birth defects (including anomalies and defects) prior to conception during early pregnancy.
or no increased risk of
is classified by the US FDA as Pregnancy
limb-reduction
Do bleeding as for pregnancy.
not administer COCs to induce withdrawal
or
in women who
Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives
Do
not use COCs during pregnancy to treat threatened or habitual abortion. URL: https://www.allcontraceptives.com/ovral-l-tablets.html
a test
use Combined oral
an increased
cardiac
(Ovral-L
Ovral-L Tablets During Pregnancy
Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) © All Contraceptives For more details on Ovral-L Tablets click here Ovral-L (Generic Ethinyl Estradiol and Levonorgestrel Tablets) by Wyeth Limited, India, a division of Pfizer. URL: https://www.allcontraceptives.com/ovral-l-tablets.html

